Supported by a $59 million Series B funding round, Mercy BioAnalytics intends to commercialize its blood-based ovarian cancer test in early 2026. Leveraging its Halo platform, which detects tumor-specific proteins on extracellular vesicles, the company aims to address ovarian cancer screening and diagnosis challenges, including management of pelvic masses. The funding will also support development of a lung cancer screening assay. Mercy plans an initial early access program targeting Boston, followed by broader metro area expansion. This advancement signifies a promising step toward noninvasive cancer detection technologies with potentially high clinical impact.